Puma Biotech (NASDAQ: PBYI) reported Q4 EPS of ($0.07), $0.12 worse than the analyst estimate of $0.05. Revenue for the quarter came in at $53.7 million versus the consensus estimate of $57.06 million.

GUIDANCE:

Puma Biotech sees Q1 2023 revenue of $43-46 million, versus the consensus of $51 million.

Puma Biotech sees FY2023 revenue of $205-210 million, versus the consensus of $227.4 million.

For earnings history and earnings-related data on Puma Biotech (PBYI) click here.